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Abstract
Background: Several small studies indicated that the genotype of KIT or platelet-derived growth factor receptor-α
(PDGFRA) contributes in part to the level of clinical effectiveness of sunitinib in gastrointestinal stromal tumor (GIST)
patients. This study aimed to correlate KIT and PDGFRA mutational status with clinical outcome metrics (progression-free
survival [PFS], overall survival [OS], objective response rate [ORR]) in a larger international patient population.
Methods: This is a non-interventional, retrospective analysis in patients with imatinib-resistant or intolerant
GIST who were treated in a worldwide, open-label treatment-use study (Study 1036; NCT00094029) in which sunitinib
was administered at a starting dose of 50 mg/day on a 4-week-on, 2-week-off schedule. Molecular status was obtained
in local laboratories with tumor samples obtained either pre-imatinib, post-imatinib/pre-sunitinib, or post-sunitinib
treatment, and all available data were used in the analyses regardless of collection time. The primary analysis compared
PFS in patients with primary KIT exon 11 versus exon 9 mutations (using a 2-sided log-rank test) and secondary analyses
compared OS (using the same test) and ORR (using a 2-sided Pearson χ2 test) in the same molecular subgroups.
Results: Of the 1124 sunitinib-treated patients in the treatment-use study, 230 (20 %) were included in this analysis, and
baseline characteristics were similar between the two study populations. Median PFS was 7.1 months. A significantly
better PFS was observed in patients with a primary mutation in KIT exon 9 (n = 42) compared to those with a primary
mutation in exon 11 (n = 143; hazard ratio = 0.59; 95 % confidence interval, 0.39–0.89; P = 0.011), with median PFS times
of 12.3 and 7.0 months, respectively. Similarly, longer OS and higher ORR were observed in patients with a primary KIT
mutation in exon 9 versus exon 11. The data available were limited to investigate the effects of additional KIT or PDGFRA
mutations on the efficacy of sunitinib treatment.
Conclusions: This large retrospective analysis confirms the prognostic significance of KIT mutation status in patients with
GIST. This analysis also confirms the effectiveness of sunitinib as a post-imatinib therapy, regardless of mutational status.
Trial registration: NCT01459757.
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Background
Gastrointestinal stromal tumors (GIST) comprise the most
common primary mesenchymal malignancies of the
gastrointestinal tract, and approximately 95 % of these tu-
mors express the cell-surface transmembrane receptor KIT
that has tyrosine kinase activity [1]. Constitutive activation
of KIT occurs in approximately 80–85 % of cases through
mutations at various sites in the transcribed sites of the
KIT proto-oncogene [1]. This is one of the earliest cellular
events responsible for the oncogenic transformation of
GIST cells and is a key driver of the disease pathogenesis
[2, 3]. Mutations occur most commonly in exon 11 (juxta-
membrane domain), followed in frequency of incidence by
exon 9 (extracellular domain) [1]. Activating mutations
also occur in the PDGFRA gene (encoding the receptor
tyrosine kinase platelet-derived growth factor receptor
[PDGFR]-α) in approximately 5–7 % of GIST cases. These
often occur mutually exclusively to KIT mutations,
highlighting their important role in the pathogenesis of
GIST [4]. Finally, there is a subset of 12–15 % of GIST
cases which lack mutations in KIT and PDGFRA but which
often harbor genomic or epigenetic aberrations in subunits
of the succinate dehydrogenase (SDH) complex [5].
Imatinib is a relatively selective small molecule inhibitor
of a limited number of tyrosine kinases—including KIT,
PDGFRA, and the intracellular ABL kinase—that has
helped to transform the management of GIST. It was
approved for the treatment of metastatic or unresectable
GIST in the USA in 2002, following a successful phase II
trial and follow-up period [6, 7]. However, the clinical ben-
efits observed in GIST patients with imatinib vary accord-
ing to KIT and PDGFRA genotype. For example, patients
with KIT exon 11-mutant GIST have a greater objective
response rate (ORR) and longer median progression-free
survival (PFS) with front-line imatinib treatment than
GIST patients with KIT exon 9-mutant or KIT/PDGFRA
“wild-type” (non-mutant) genotypes [8, 9]. Furthermore,
the majority of patients with advanced GIST ultimately de-
velop resistance to imatinib, which can either occur rapidly
within 6 months of initiating therapy (primary resistance),
or can appear with delay after 1 to more than 10 years on
imatinib therapy. This delayed resistance usually occurs
due to acquisition of secondary mutations in KIT or
PDGFRA [10]. In the case of imatinib-resistant KIT-mutant
GIST, these mutations cluster in the ATP-binding pocket
(encoded by exons 13 and 14), and the activation loop
(encoded by exons 17 and 18) of the kinase domain, and
occur almost exclusively in the same gene and allele as the
primary oncogenic driver mutation [10–13].
Sunitinib is a multi-targeted oral inhibitor of KIT,
PDGFRs, vascular endothelial growth factor (VEGF) re-
ceptors (VEGFRs), and several other receptor tyrosine ki-
nases [14–17]. It has shown clinically meaningful efficacy
in phase I–III trials in imatinib-resistant or -intolerant
patients with advanced GIST [18–21], and continues to be
used worldwide after imatinib in this patient setting. How-
ever, as is the case with imatinib, the clinical effectiveness
of sunitinib is influenced by mutations in the KIT and
PDGFRA genes. Findings from several small studies indi-
cate that endpoints such as PFS and overall survival (OS)
are significantly longer for patients with primary (pre-ima-
tinib) KIT exon 9 mutations compared with those with
KIT exon 11 mutations in both Caucasian [22, 23] and,
more recently, Asian populations [24]. Secondary muta-
tion status may also have a prognostic role in sunitinib
therapy success [22, 25–27], with data from small num-
bers of patients suggesting that mutation in exons 17 or
18 could confer some degree of resistance to the drug.
In the current study (Study 1199), we retrospectively ex-
amined correlations between clinical outcomes and KIT/
PDGFRA mutational status in a subset of imatinib-resistant
or -intolerant patients with GIST participating in a world-
wide, open-label treatment-use study (Study 1036) [28].
Methods
Study design and patient selection
The current study (Study 1199; ClinicalTrials.gov identifier:
NCT01459757) was designed as a non-interventional,
retrospective analysis of KIT/PDGFRA mutation status data
from an international open-label non-randomized, open-
label treatment-use trial, Study 1036 (NCT00094029),
which provided access to sunitinib to appropriate patients
with GIST prior to availability of this agent in various coun-
tries around the world [28].
In the treatment-use study (Study 1036), 1131 patients
were enrolled from 34 countries worldwide between
September 2004 and December 2007, with 1124 patients
receiving ≥1 dose of sunitinib (intent-to-treat [ITT] popu-
lation). Key eligibility criteria included: age ≥18 years (how-
ever, protocol amendments also allowed younger patients
to enroll), histologically confirmed metastatic and/or unre-
sectable GIST not amenable to standard therapy, failed
prior treatment with imatinib (indicated by disease pro-
gression or intolerance), potential to derive clinical benefit
from sunitinib treatment, and resolution of all acute toxic
effects of any prior therapy/surgery to grade ≤1. Sunitinib
was administered at a starting dose of 50 mg/day on a 4-
week-on, 2-week-off schedule (alternative dosing schedules
were permitted following a protocol amendment in May
2006, which allowed patients to switch to 37.5 mg on a
continuous daily dosing schedule). Treatment continued
for as long as it was deemed to be clinically beneficial, as
judged by the investigator. Tumor responses were assessed
radiologically.
To be included in this retrospective sub-study (Study
1199), patients must have taken ≥1 dose of sunitinib in
Study 1036, and have given consent for inclusion in the
retrospective analysis (either personally or via the
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institutional review board/ethics committees if expired
or lost to follow-up). Selection of participants was
based upon the willingness of individual clinical study
centers to participate, the availability of tumor muta-
tional analysis data or retrievable tumor specimens for
mutational analysis, and on the consent of patients.
Additional outcomes data (PFS, OS, and ORR) from
after the cutoff date of Study 1036 (July 2008), or not
previously collected in Study 1036, were collated for
analysis, where available and once the appropriate con-
sent was obtained.
This study was conducted in accordance with the
Declaration of Helsinki and Good Clinical Practice
guidelines, and the protocol approved by the relevant in-
stitutional review board/independent ethics committees
(see the Additional file 1 for a full list of the participat-
ing sites).
Study objectives
The primary objective of this retrospective study was to
correlate GIST genotype (specifically the KIT genotype
within tumor cells) with clinical outcome (PFS and OS) in
imatinib-resistant or intolerant patients with GIST treated
with sunitinib. The secondary objective was to confirm
the clinical efficacy of sunitinib therapy in imatinib-
resistant or intolerant patients with advanced GIST.
Assessments and analyses
Mutational status
Tumor tissue for mutational status assessment was
obtained at any time point on one or more occasion (pre-
imatinib, post-imatinib/pre-sunitinib, or post-sunitinib
treatment). Mutational status of the relevant kinase targets
was determined by local laboratory analyses. KIT mutation
locations were noted where available (e.g. exon 9, exon 11,
and exon 13), together with the location of PDGFRA mu-
tations (e.g. exon 12, exon 18). If no mutations were
found, patients were classified as either “KIT and PDGFRA
wild-type”, when all key exons (KIT exons 9, 11, 13, and
17; PDGFRA exons 12 and 18) were assessed and no mu-
tations were found, or “mutation-absent” if no mutations
were found, but only a subset of the key exons were
assessed. Available mutational data were used in all ana-
lyses, regardless of the time of collection.
Efficacy analysis
The definition of PFS was the time from date of enroll-
ment in Study 1036 to first progression of disease (PD)
or death for any reason in the absence of documented
PD (up to last dose date + 28 days), whichever occurred
first. OS was defined as the time from date of enroll-
ment in Study 1036 to date of death due to any cause.
The definition of ORR was the percent of patients
achieving a confirmed complete response (CR) or partial
response (PR) in Study 1036, according to the Response
Evaluation Criteria in Solid Tumors (RECIST) version
1.0 [29]. Confirmed responses were those that persisted
on repeat imaging at least 4 weeks after the initial
documentation of response. Patients who did not have
on-study radiographic tumor re-evaluation, who received
anti-tumor treatment other than the study medication
prior to reaching a CR or PR, or who died, progressed,
or dropped out for any reason prior to reaching a CR or
PR were counted as non-responders in the assessment
of ORR.
Adverse events
Adverse events (AEs) were assessed until ≤28 days after
the last dose of sunitinib and graded using National
Cancer Institute Common Terminology Criteria for
Adverse Events version 3.0.
Statistical analysis
Analyses were performed for all patients who received ≥1
dose of sunitinib and from whom consent was obtained
(full analysis set). The sample size for this study was calcu-
lated using PFS assumptions that were based on the
results of a phase II sunitinib study [22].
In the study, PFS (in months) was calculated as: (first
event date − enrollment date +1)/30.4. Additionally, OS
(in months) was calculated as: (date of death − enroll-
ment date +1)/30.4. For patients still alive at the time of
the analysis or without confirmation of death, the OS
time was censored on the last date they were known to
be alive. Patients lacking data beyond enrollment had
their OS times censored at enrollment with a duration
of 1 day. PFS and OS were summarized using Kaplan–
Meier methods.
The median PFS or OS time and corresponding 2-
sided 95 % confidence intervals (CIs) were also calcu-
lated based on KIT mutational status. A 2-sided log-rank
test was used to compare PFS (primary analysis) or OS
between patients with primary KIT exon 9 and exon 11
mutations, with a significance level of 0.05. The hazard
ratio (HR) and its 95 % CIs were estimated. Cox propor-
tional hazard models were used to evaluate whether
other baseline characteristics, including age and per-
formance status, could also influence PFS and OS over
and above primary mutational status.
The number and percent of patients achieving an ob-
jective response (CR or PR) were summarized along with
the corresponding exact 2-sided 95 % CI based on KIT
mutational status. In this regard, ORR by primary KIT
mutational status (exon 11 versus exon 9) was compared
using a 2-sided Pearson χ2 test to significance level 0.05,
with corresponding 2-sided 95 % CIs estimated using
the exact method based on the F-distribution.
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Results
Study disposition and baseline characteristics
Of the 1124 patients in the treatment-use, Study 1036,
who received ≥1 dose of sunitinib, 230 (20 %) were in-
cluded in this retrospective analysis (Study 1199), based
upon clinical center participation, patient consent, and
genotype data availability. Despite the non-random selec-
tion of patients in Study 1199, the baseline demographic
and clinical characteristics of these patients were represen-
tative of the larger population in Study 1036 (Table 1).
Both studies had a similar median age (60 years in this
study; 59 years in Study 1036). Additionally, the studies
had similar distributions of patients by sex (60 % male in
both studies), race (80 % and 76 % white in this study and
Study 1036, respectively), and baseline Eastern Cooperative
Oncology Group (ECOG) performance status (87 % and
84 % ECOG 0 or 1 in this and Study 1036, respectively).
The respective median times since original diagnosis were
186 and 171 weeks in studies 1199 and 1036, and a 600–
800 mg maximum prior imatinib dose was the most
frequent in both studies (43 % in Study 1199 and 47 % in
Study 1036). The outcome of PD within and beyond 6
months of the start of prior imatinib therapy was seen
in 13 % and 79 % of patients in Study 1199, respect-
ively, and 14 % and 77 % of patients in Study 1036,
respectively. A CR or PR to prior imatinib treatment was
observed in 39 % of patients in Study 1199 and 36 % of pa-
tients in Study 1036. Overall, 8 % and 9 % of patients were
intolerant to prior imatinib therapy in studies 1199 and
1036, respectively. Additional treatment history (i.e. other
than imatinib) of patients in Study 1199 and Study 1036
was also comparable: systemic therapy other than imatinib
was received by 21 % and 20 % of patients, respectively;
previous surgery was performed in 99 % and 98 % of
patients, respectively; and previous radiotherapy was
received by 7 % of patients in both studies.
Mutational status of KIT and PDGFRA target genes
Table 2 and Additional file 1: Table S1 show KIT and
PDGFRA mutational status data for the full analysis set of
Study 1199. For the analysis of primary KIT mutational
status, samples were collected from 148 patients, pre-
imatinib treatment, from 68 patients, post-imatinib/pre-
sunitinib treatment, and from 24 patients, post-sunitinib
treatment (see Additional file 1: Table S2 for the distribu-
tion of primary KIT exon 9 and exon 11 mutations
according to sampling time point). Overall, 86 % of pa-
tients had any primary KIT mutation. The most frequent
KIT primary mutations occurred in exon 11 (62 %) and
exon 9 (18 %), and 4 % of patients were classified as wild-
type (no mutation in KIT exons 9, 11, 13, and 17) (Table 2).
Secondary KIT mutations occurred in 11 % of patients
and were observed most frequently in exons 13 and 17 (in
5 % of patients each). Third KIT mutations were only
observed in two patients, although this information was
classified as “absent” or “missing” in 99 % of patients
(Additional file 1: Table S1).
Demographic and baseline clinical characteristics were
generally similar across all primary KIT mutational status
groups and the study population as a whole (Table 3).
However, as expected, when considering prior imatinib
therapy, the proportion of patients with PD within 6
months of treatment initiation was significantly lower
among those with exon 11 mutations (3 %) when com-
pared with other mutational groups (17–43 %). Con-
versely, PD seen beyond 6 months of imatinib treatment
initiation was observed at a higher frequency among those
with exon 11 mutations (92 %) compared with those in
other mutational groups (44–62 %). Similarly, patients
Table 1 Baseline clinical characteristics in Studies 1199 and 1036
Characteristic Study 1199
(N = 230)
Study 1036
(N = 1124)
Age, median (range), years 60 (11−83) 59 (10−92)
Male sex, n (%) 139 (60) 672 (60)
ECOG performance status,a n (%)
0 87 (38) 420 (37)
1 114 (50) 521 (46)
2 24 (10) 135 (12)
3 3 (1) 33 (3)
4 0 5 (<1)
Time since original diagnosis, median
(range), weeks
186 (12–773) 171 (3−1584)
Maximum prior imatinib dose,b n (%)
≤ 400 mg 71 (31) 353 (31)
> 400–600 mg 58 (25) 212 (19)
> 600–800 mg 99 (43) 532 (47)
> 800 mg 2 (1) 24 (2)
Outcome with prior imatinib therapy,c
n (%)
PD within 6 months of start 30 (13) 153 (14)
PD beyond 6 months of start 181 (79) 871 (77)
Intolerance 19 (8) 99 (9)
Best response to prior imatinib,d n (%)
CR 8 (3) 56 (5)
PR 82 (36) 353 (31)
Stable disease 93 (40) 391 (35)
PD 39 (17) 288 (26)
Not applicable 7 (3) 31 (3)
Study 1199: full analysis population; Study 1036: ITT population
CR complete response, ECOG Eastern Cooperative Oncology Group, ITT intent-
to-treat, PD progressive disease, PR partial response
aData missing: Study 1199, n = 2; Study 1036, n = 10
bData missing: Study 1036, n = 3
cData missing: Study 1036, n = 1
dData missing: Study 1199, n = 1; Study 1036, n = 5
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with exon 11 mutations displayed a better response (CR +
PR) to prior imatinib treatment when compared with
those with exon 9 mutations (52 % and 21 %, respectively).
Primary PDGFRA mutational status was missing for 50 %
of patients, and primary PDGFRA mutations were observed
in only 12 patients (5 %), most often in exon 18 (n = 5). No
secondary PDGFRA mutations were observed.
Sunitinib efficacy overall and by mutational status
It was possible to analyze the efficacy of sunitinib treat-
ment in the context of patients with primary KIT exon 9
or exon 11 mutations. Unfortunately, the available data
were too limited to investigate the effects of additional
KIT mutations, or the effects of PDGFRA mutations, on
efficacy outcomes following sunitinib treatment. Simi-
larly, the effect of the wild-type genotype could not be
investigated due to the limited number of patients in this
category (n = 9).
Correlation between KIT mutations and progression-free
survival with sunitinib
Overall, median PFS in the Study 1199 patient popula-
tion was representative of Study 1036 following sunitinib
treatment: 7.1 months (95 % CI: 6.4–8.1 months) and
7.6 months (95 % CI: 6.8–8.1 months), respectively.
With sunitinib treatment, patients with a primary KIT
mutation in exon 9 displayed a significantly better PFS
compared with those with a primary mutation in exon 11
(HR = 0.59; 95 % CI: 0.39–0.89; P = 0.011; Fig. 1), with
median PFS times of 12.3 and 7.0 months, respectively. In
addition, the proportion of patients who progressed or
died at the time of the analysis was lower (69 %) for pa-
tients with primary KIT exon 9 mutations compared with
those with primary KIT exon 11 mutations (83 %). The
Cox proportional hazards analysis of PFS revealed that
neither age (<59 versus ≥59 years; HR = 1.02; 95 % CI:
0.73–1.41) nor baseline ECOG performance status (<2
versus ≥2; HR = 0.74; 95 % CI: 0.45–1.20) had a significant
additional effect on PFS.
Correlation between KIT mutations and overall survival
with sunitinib
Across the whole study population, OS was similar be-
tween studies 1199 and 1036, with a median of 19.3
months (95 % CI: 15.9–22.5 months) and 16.6 months
(95 % CI: 14.9–18.0 months) [28], respectively.
As with PFS, patients with a primary KIT mutation in
exon 9 displayed a significantly better OS when com-
pared with those with a primary KIT mutation in exon
11 (HR = 0.55; 95 % CI: 0.38–0.80; P = 0.002; Fig. 2), with
median OS times of 26.3 and 16.3 months, respectively.
Furthermore, the proportion of patients who had pro-
gressed or died at the time of the analysis tended to be
lower (83 %) for patients with primary exon 9 mutations
than for those with primary exon 11 mutations (92 %).
The Cox proportional hazards analysis of OS revealed
ECOG performance status (<2 versus ≥2) had a signifi-
cant effect on OS in addition to mutational status (HR
for ECOG = 0.58; 95 % CI: 0.37–0.91), but age (<59 ver-
sus ≥59 years) did not (HR = 1.01; 95 % CI: 0.74–1.37).
Correlation between KIT mutations and overall objective
response rates with sunitinib
The overall ORR was similar between the two study popu-
lations: 8 % (95 % CI: 5–12) and 8 % (95 % CI: 6–10) for
studies 1199 and 1036 [28], respectively.
In the present analysis, patients with a primary KIT
exon 9 mutation had a significantly higher ORR than
those with a primary KIT exon 11 mutation (19 % versus
6 %; P = 0.012; Table 4). Of the eight patients with pri-
mary KIT mutations in exon 9 (n = 42) who achieved an
objective response (CR + PR), two achieved a CR (5 %
overall; 25 % of the objective response group). All nine
of the responses observed in patients with primary KIT
exon 11 mutations (n = 143) were PRs.
Table 2 Primary KIT and PDGFRA mutational status in Study
1199
Mutational status Study 1199 (N = 230) n (%)
KIT primary mutation
Any 197 (86)
Exon 9 42 (18)
Exon 11 143 (62)
Exon 13 5 (2)
Exon 17 6 (3)
Other 1 (<1)
Wild-type 9 (4)
Absenta 23 (10)
Missingb 1 (<1)
PDGFRA primary mutation
Any 18 (8)c
Exon 10 1 (<1)
Exon 12 1 (<1)
Exon 18 5 (2)
Other 11 (5)c
Absenta 97 (42)
Missingb 115 (50)
PDGFRA, platelet-derived growth factor receptor-α
aMutational status was classified as “absent” if no mutations were found but
only a subset of the key exons were assessed
bMutational status was classified as “missing” if no assessments
were performed
c6 patients (3%) with tumor genotypes classified as "other" were wild-type for
PDGFRA mutations status
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Table 3 Baseline clinical characteristics based on primary KIT mutational statusa
Characteristic Absent
(n = 23)
Exon 9
(n = 42)
Exon 11
(n = 143)
Exon 13
(n = 5)
Exon 17
(n = 6)
Wild-type
(n = 9)
Age, median (range), years 54 (11–67) 58 (26–79) 61 (27–83) 67 (31–75) 62 (44–79) 46 (33–64)
Male sex, n (%) 10 (43) 29 (69) 88 (62) 4 (80) 3 (50) 4 (44)
ECOG performance status,b n (%)
0 10 (43) 20 (48) 50 (35) 1 (20) 3 (50) 2 (22)
1 9 (39) 17 (40) 73 (51) 4 (80) 3 (50) 7 (78)
2 4 (17) 4 (10) 16 (11) 0 0 0
3 0 0 3 (2) 0 0 0
4 0 0 0 0 0 0
Time since original diagnosis, median (range), weeks 92 (12–310) 142 (22–702) 209 (16–680) 118 (33–236) 197 (21–545) 177 (30–773)
Maximum prior imatinib dose, n (%)
≤ 400 mg 8 (35) 10 (24) 51 (36) 0 0 2 (22)
> 400–600 mg 7 (30) 8 (19) 37 (26) 4 (80) 2 (33) 0
> 600–800 mg 8 (35) 24 (57) 53 (37) 1 (20) 4 (67) 7 (78)
> 800 mg 0 0 2 (1) 0 0 0
Outcome with prior imatinib therapy,c n (%)
PD within 6 months of start 10 (43) 10 (24) 4 (3) 2 (40) 1 (17) 3 (33)
PD beyond 6 months of start 12 (52) 26 (62) 131 (92) 3 (60) 3 (50) 4 (44)
Intolerance 1 (4) 6 (14) 8 (6) 0 2 (33) 2 (22)
Best response to prior imatinib,d n (%)
CR 0 2 (5) 6 (4) 0 0 0
PR 3 (13) 7 (17) 68 (48) 0 3 (50) 1 (11)
Stable disease 9 (39) 22 (52) 51 (36) 2 (40) 2 (33) 6 (67)
PD 10 (43) 10 (24) 14 (10) 3 (60) 1 (17) 1 (11)
Not applicable 1 (4) 1 (2) 4 (3) 0 0 0
CR complete response, ECOG Eastern Cooperative Oncology Group, PD progressive disease, PR partial response
aData not shown for other mutations (n = 1) or data missing (n = 1)
bData not shown for ECOG performance status missing (exon 9, n = 1; exon 11, n = 1; all other groups, n = 0)
cNo data missing
dData not shown for response missing (wild-type, n = 1; all other groups n = 0)
Fig. 1 Progression-free survival (PFS) by primary KIT mutational
status in Study 1199. CI, confidence interval; HR, hazard ratio;
ITT, intent-to-treat
Fig. 2 Overall survival (OS) in Study 1199 by primary KIT mutational
status. CI, confidence interval; HR, hazard ratio; ITT, intent-to-treat
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Adverse events
In general, the safety profile observed with sunitinib in
the 1199 study population was similar to the profile seen
in Study 1036. Treatment-related AEs were observed in
93 % and 92 % of patients in studies 1199 and 1036,
respectively. Serious treatment-related AEs occurred in
21 % and 22 % of patients, respectively. The proportion
of patients experiencing AEs leading to treatment dis-
continuation was 30 % for both studies.
Discussion
Although effective in the vast majority of patients, the
eventual evolution of resistance to imatinib is common
in patients with GIST, with resistance observed in more
than 80 % of evaluable patients during long-term follow-
up in a phase III trial [30]. Sunitinib, a multi-targeted in-
hibitor of KIT and other receptor tyrosine kinases, is an
important therapy for patients with GIST who become
resistant to, or are intolerant of, imatinib. This non-
interventional retrospective analysis (Study 1199) pro-
vided further evidence that imatinib-resistant or -intoler-
ant patients with GIST experience clinical benefit from
sunitinib treatment, regardless of the mutational status
of their tumor. No mutational subsets of patients were
found in the current study in which the drug was in-
active, although this retrospective analysis had limited
ability to assess very rare mutational subtypes or impact
of various mutations in PDGFRA.
Clinical benefit associated with sunitinib-induced con-
trol of GIST is thought to be influenced by KIT muta-
tional status [22, 24–26, 31], and identifying those
patients who are most likely to benefit from sunitinib
treatment is desirable for both patients and clinicians.
The current study aimed to correlate KIT mutational
status data with clinical outcome in sunitinib-treated pa-
tients with imatinib-resistant or -intolerant GIST. The
primary analysis revealed that individuals with a primary
KIT exon 9 mutation in their tumor achieved better clin-
ical outcomes during treatment with sunitinib than
those with a primary KIT exon 11 mutation, across all
three efficacy measures (PFS, OS, and ORR). Patients
with KIT exon 9 mutations experienced a 41 % reduc-
tion in risk of progression, a 45 % reduction in the risk
of death, and ORR that was three times higher, com-
pared to those with primary KIT mutations in exon 11.
The observation that patients with GIST with a pri-
mary KIT mutation in exon 9 present with better out-
comes following sunitinib treatment compared with
those with a primary KIT mutation in exon 11 is consist-
ent with previous studies in both Caucasian [22, 23] and
Asian [24] populations. However, these studies involved
relatively small patient sets of less than 100 subjects,
resulting in low numbers of individuals within the differ-
ent mutation subgroups. In contrast, the present study
utilized data from a much larger cohort of 230 patients,
including 42 harboring KIT exon 9 mutations and 143
with exon 11 mutations. The favorable outcomes in
GIST with primary KIT mutations in exon 9 treated with
sunitinib are consistent with in-vitro data, demonstrat-
ing greater potency of sunitinib over imatinib against
exon 9 mutant KIT, and similar potency of each drug
against exon 11 mutant KIT [22]. This observation could
be due to the differential effect that mutation within
each site has upon KIT receptor structure [32, 33].
Table 4 Best objective tumor response (investigator assessment) in Study 1199 by primary KIT mutational status, and in the overall
ITT population of Study 1036
Response parameter Study 1199 1036 ITT
(N = 1124)Exon 9 (n = 42) Exon 11 (n = 143)
Best confirmed tumor response,a n (%)
CR 2 (5) 0 10 (1)
PR 6 (14) 9 (6) 78 (7)
Stable disease 29 (69) 86 (60) 639 (57)
PD 4 (10) 31 (22) 237 (21)
Not evaluable 0 1 (1) 2 (<1)
Missing 1 (2) 16 (11) 158 (14)
Confirmed objective responses,b n (%) 8 (19) 9 (6) 88 (8)
95 % exact CI, % 9−34 3−12 6−10
Difference in ORR: exon 9 vs. exon 11, % 13 NA
95 % CI <1−25 NA
P-value (two-sided Pearson χ2) 0.012 NA
CI confidence interval, CR complete response, ITT intent-to-treat, NA not applicable, PD progressive disease, PR partial response
aTumor assessment data obtained ≤28 days after last dose of study drug
bCR + PR
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Despite the non-randomized patient selection for this
retrospective analysis, the baseline demographic and dis-
ease characteristics were similar to those observed in the
parent Study 1036, which enrolled over 1000 patients
with GIST from centers worldwide [28]. In addition, dif-
ferences in dosing were unlikely to have impacted the
findings. Previously reported post-hoc analyses of Study
1036 found that patients who received sunitinib on an
alternative dosing schedule versus those who received
only the initial dosing schedule had prolonged treat-
ment, which may have led to improved outcomes, in-
cluding prolonged TTP and OS [28]. However, among
the 230 patients in the current study, 108 (47 %) had a
dose reduction, similar to the number of patients in the
parent study (43 %). Furthermore, the numbers of pa-
tients with dose reductions in the exon 9 and exon 11
subgroups in this study were comparable (both 48 %).
Therefore, the results from the current study are likely
to be broadly representative of the usual population that
clinicians will see in everyday practice. In this respect, it
is noteworthy that the distribution of primary KIT and
PDGFRA mutations in our study was consistent with
previous studies among patients with GIST [1, 8, 22].
Overall, 86 % of participants in our analysis had a pri-
mary mutation in KIT and 5 % had a primary mutation
in PDGFRA.
Other secondary mutations may also influence response
to sunitinib [22, 25–27]. Data in small numbers of patients
indicate that mutations in exons 17 and 18 may confer
some degree of resistance to the drug. Unfortunately, in-
formation on secondary and tertiary mutation status of
the patients in this study was not analyzable due to the
limited availability of data. This was because, given the
retrospective nature of this analysis, in some cases, only
one biopsy was taken for each patient and also because bi-
opsy collection timings varied between patients. Some bi-
opsies were collected before beginning first-line treatment
with imatinib (pre-imatinib, n = 148), some during or after
completion of first-line treatment with imatinib, but
before beginning treatment with sunitinib (post-imatinib/
pre-sunitinib; n = 68), and some after the beginning or
after completion of treatment with sunitinib (post-suniti-
nib; n = 24). This represents a limitation of this study. It
should also be noted that only a subset of patients in the
treatment-use study (Study 1036) were included in this
correlation study; thus, this selected group of patients may
not be fully representative of the pool of patients with
secondary mutations. Finally, it should be noted that dif-
ferent mutational subtypes of KIT exon 9 and 11 may have
a differential impact on treatment outcome (e.g. gastric
GISTs with exon 11 deletions are more aggressive than
those with substitutions) [34]; however, due to the limited
number of patients, this level of analysis could not be per-
formed in the current study.
Combined with the existing evidence, our data suggest
that obtaining information on KIT mutations from pa-
tients before the start of treatment would allow clinicians
to predict who are most likely to experience resistance to
primary imatinib therapy, to evaluate which patients
would benefit the most from sunitinib therapy, and also to
aid in our understanding of why particular patients re-
spond better than others. The data also support stratifica-
tion by mutational status in future trials comparing
sunitinib and novel agents. However, extensive intra- and
inter-lesional heterogeneity of resistance mutations in
patients with clinically progressing GIST is apparent, with
up to five different secondary mutations observed in dif-
ferent metastases and up to two in the same metastasis in
one study [35]. As a result of this, the information that
can be generated from mutational analysis of a discrete,
single tumor biopsy at the time of progression may
confound subsequent treatment decisions. In the future, a
meta-analysis of studies will be worthwhile to study the
influence of rare mutations on outcomes in patients
treated with sunitinib, and next-generation sequencing
may provide more information on predominant and
minor mutations that influence the efficacy of sunitinib
and other agents. In addition, it must be remembered that
mutational status is not the only prognostic factor that
influences the clinical outcome of patients with GIST on
receptor tyrosine kinase therapy, with initial low tumor
volume, female gender, and CD34 positivity predicting
higher PFS in a recent study considering patients treated
with imatinib [36]. There is also evidence that exon 9-
mutated GIST metastasizes significantly more often to the
peritoneum than to the liver and that exon 9 mutations
per se may not have prognostic relevance [37]; however,
we do not have the level of data required to test a possible
correlation of primary KIT mutation with metastasis
status and location. Another important element of the
multiple mechanisms of action of sunitinib as it pertains
to GIST tumor biology is the complexity of the angiogen-
esis process. Expression of VEGF (a highly pro-angiogenic
ligand of VEGFR2, which is another target of sunitinib but
not of imatinib) has been shown to be higher in wild-type
GISTs than in KIT-mutant GIST [38], and little is known
about the angiogenic status at the time of progression on
imatinib, which is likely to play a role in the mechanisms
of resistance, as with many other targeted therapies. Fi-
nally, a recently reported study of theranostic biomarkers
that identified potential therapies beyond tyrosine kinase
inhibitors for GIST, including various cytotoxics and non-
KIT/PDGFRA targeted therapies, underscores the hetero-
geneous nature of GIST [39].
Conclusions
In summary, this large retrospective study provides a ro-
bust analysis of the influence of KIT mutational status
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on clinical outcomes with sunitinib in patients with ad-
vanced GIST following failure of imatinib due to resistance
or intolerance. The study also confirms the effectiveness of
sunitinib as a post-imatinib therapy in patients, regardless
of the mutational status of their tumor. It also confirms
differential activity in KIT exon 9 versus exon 11 patients
and adds to the limited data available on sunitinib activity
in patients with other GIST mutations or SDH-deficient
(“KIT/PDGFRA wild-type”) tumors. These data should give
clinicians increased confidence in the effectiveness of suni-
tinib in all of these particular GIST patient subsets.
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